Semax and Selank Research Guide
Two synthetic heptapeptides that end in Pro-Gly-Pro: Semax, an ACTH(4-10) analogue, and Selank, a tuftsin analogue. Sold as Semax 10mg, Selank 10mg and Semax + Selank 20mg.
What is Semax and Selank?
Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, an analogue of the adrenocorticotropin fragment ACTH(4-10) (Dolotov et al., 2006). Selank is a synthetic analogue of tuftsin, a natural immunomodulatory tetrapeptide (Kolomin et al., 2014), with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro.
Both peptides end in the Pro-Gly-Pro sequence, part of the glyproline family of regulatory peptides studied for their stability (Ashmarin et al., 2003). We supply Semax 10mg, Selank 10mg, and Semax + Selank 20mg, a vial holding 10 mg of each.
Research areas studied
The findings below come from published cell-based and animal research. They describe what studies have examined and reported, not effects of any research material.
Semax and the BDNF system
In rats, a single application of Semax increased hippocampal levels of BDNF protein and phosphorylation of its receptor trkB, and raised BDNF and trkB mRNA. Animals given Semax showed more conditioned avoidance reactions (Dolotov et al., 2006).
Semax and monoamine systems
In rodents, Semax raised striatal levels of the serotonin metabolite 5-HIAA. On its own it did not change dopamine levels, but given before D-amphetamine it enhanced the dopamine release and locomotor activity that D-amphetamine produced (Eremin et al., 2005). In rat blood, Semax was more stable than ACTH(4-10) against most degrading enzymes (Potaman et al., 1991).
Selank and gene expression
In the rat frontal cortex, Selank changed the expression of 45 of 84 neurotransmission-related genes 1 hour after administration, with a pattern that correlated with GABA. The authors proposed allosteric modulation of the GABAergic system as one possible mechanism (Volkova et al., 2016). In mouse spleen, Selank and its fragment Gly-Pro altered the expression of inflammation-related genes such as C3 and Casp1 within 30 to 90 minutes (Kolomin et al., 2014).
Regulatory status and limits of the evidence
FDA’s compounding safety page lists both selank acetate and semax among nominated substances whose nominations were withdrawn, citing possible immunogenicity and limited safety information. Most published research on both peptides comes from a small number of research groups and uses rodent models.
Storage and handling
Like most research peptides, Semax and Selank is normally supplied for laboratory use as a lyophilized (freeze-dried) powder in a sealed vial. Check the label and the batch COA for the exact form of your lot. Zero Zero Collection recommends keeping vials refrigerated at 2 to 8 ยฐC and protected from light, as stated on every product page. Let a refrigerated vial reach room temperature before opening it so moisture does not condense on the powder.
When a lab reconstitutes lyophilized material, standard practice is to add a sterile diluent such as bacteriostatic water slowly down the inside wall of the vial, then swirl gently rather than shake. The volume depends on the concentration a protocol calls for, so follow your own lab’s validated method. Label the vial with the date, keep reconstituted material refrigerated, and follow your institution’s guidance on how long a solution stays usable.
Quality and documentation
We supply Semax and Selank as research material in a sealed, lot-traceable vial. Match the lot number on your vial to your order records, and contact our team at [email protected] with any lot-specific questions.
Semax and Selank FAQ
What do Semax and Selank have in common?
Both are synthetic heptapeptides that end in the Pro-Gly-Pro sequence. Semax is built on a fragment of ACTH and Selank on tuftsin.
What is in the Semax + Selank 20mg vial?
10 mg of Semax and 10 mg of Selank in one vial, 20 mg in total.
Are Semax and Selank approved drugs in the US?
No. FDA lists both among bulk substances whose compounding nominations were withdrawn.
References
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Brain Res. PubMed 16996037
- Eremin KO, Kudrin VS, Saransaari P, et al. (2005). Neurochem Res. PubMed 16362768
- Potaman VN, Alfeeva LY, Kamensky AA, et al. (1991). Biochem Biophys Res Commun. PubMed 1851003
- Volkova A, Shadrina M, Kolomin T, et al. (2016). Front Pharmacol. PubMed 26924987
- Kolomin T, Morozova M, Volkova A, et al. (2014). Mol Immunol. PubMed 24291245
- Ashmarin IP, Bakaeva ZV, Vas'kovskiฤญ BV, et al. (2003). Patol Fiziol Eksp Ter. PubMed 14682258
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed October 28, 2026. fda.gov
For research use only. Not for human consumption. This guide summarizes published scientific literature for laboratory research context. It is not medical advice, dosing guidance or a claim of safety or effectiveness for any use in people or animals.